Compass Therapeutics, Inc. CMPX
Price alert —
Sign in to get a one-time email the moment CMPX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · CMPX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare CMPX vs peers
Line CMPX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with CMPX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 19 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | -0.10 | -0.10 | — | -4.1% |
| 2026-03-05 | -0.09 | -0.09 | -2.6% | -0.4% |
| 2025-11-05 | -0.08 | -0.13 | +39.6% | +4.7% |
| 2025-08-11 | -0.14 | -0.12 | -19.5% | -5.1% |
| 2025-05-08 | -0.12 | -0.11 | -10.2% | +2.2% |
| 2025-02-27 | -0.11 | -0.09 | -16.5% | -0.7% |
| 2024-11-12 | -0.08 | -0.11 | +27.3% | -5.6% |
| 2024-08-12 | -0.10 | -0.09 | -5.3% | +6.2% |
| 2024-05-13 | -0.08 | -0.11 | +25.0% | +3.5% |
| 2024-03-21 | -0.11 | -0.09 | -25.0% | -4.9% |
| 2023-11-09 | -0.08 | -0.11 | +25.9% | -3.7% |
| 2023-08-03 | -0.09 | -0.08 | -15.4% | -5.3% |
| 2023-05-04 | -0.06 | -0.11 | +45.5% | +11.8% |
| 2023-03-15 | -0.10 | -0.11 | +9.1% | -3.9% |
| 2022-11-09 | -0.12 | -0.12 | +4.0% | -2.6% |
| 2022-08-01 | -0.08 | -0.07 | -6.7% | -0.4% |
| 2022-05-09 | -0.07 | -0.13 | +46.1% | +0.0% |
| 2022-03-18 | -0.04 | -0.06 | +39.0% | +6.2% |
| 2021-11-12 | -0.10 | -0.11 | +9.1% | +1.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| CMPX ★ | $0B | — | -4.4 | — | -2.5 | 2.0 | — | — | — | -8.14% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 195.95%
| Holder | Shares | % out |
|---|---|---|
| Tang Capital Management, LLC | 16,790,809 | 32.21% |
| Orbimed Advisors LLC. | 15,219,994 | 29.20% |
| Suvretta Capital Management, LLC | 14,307,379 | 27.45% |
| Vivo Capital, LLC | 9,545,466 | 18.31% |
| Blackrock Inc. | 9,506,080 | 18.24% |
| Adage Capital Partners GP L.L.C. | 8,486,500 | 16.28% |
| Enavate Sciences Gp, LLC | 7,788,150 | 14.94% |
| BVF Inc. | 7,764,842 | 14.90% |
| State Street Corporation | 6,694,976 | 12.84% |
| Vanguard Capital Management LLC | 6,037,175 | 11.58% |
Insider activity · 90d
2 buys / 0 sells · ratio 2.0 · Finnhub
- Anderman Jonathan BUY 196,000 @ $1.89
- Lerner Neil BUY 397,500 @ $1.89
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-01 | FORM 8-K | view · |
| 8-K | 2026-06-23 | FORM 8-K | view · |
| 8-K | 2026-06-11 | FORM 8-K | view · |
| 10-Q | 2026-05-05 | FORM 10-Q | view · |
| 8-K | 2026-05-05 | FORM 8-K | view · |
| 4 | 2026-04-29 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-29 | Insider transaction (Form 4) | view · |
| DEF 14A | 2026-04-29 | DEF 14A | view · |
| 8-K | 2026-04-27 | FORM 8-K | view · |
| 10-K | 2026-03-05 | FORM 10-K | view · |
| 8-K | 2026-03-05 | FORM 8-K | view · |
| 4 | 2026-02-10 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-12 | Insider transaction (Form 4) | view · |
| 8-K | 2026-01-06 | FORM 8-K | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2025-11-18 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-11-05 | FORM 10-Q | view · |
| 8-K | 2025-11-05 | FORM 8-K | view · |
| 8-K | 2025-08-13 | 8-K | view · |
| 10-Q | 2025-08-11 | FORM 10-Q | view · |
| 8-K | 2025-08-11 | FORM 8-K | view · |
| 8-K | 2025-06-12 | FORM 8-K | view · |
| 4 | 2025-05-27 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-05-08 | FORM 10-Q | view · |
| 8-K | 2025-05-08 | FORM 8-K | view · |
| DEF 14A | 2025-04-29 | DEF 14A | view · |
| 4 | 2025-04-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-08 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-08 | Insider transaction (Form 4) | view · |
| 8-K | 2025-04-01 | FORM 8-K | view · |
| 10-K | 2025-02-27 | FORM 10-K | view · |
| 8-K | 2025-02-27 | FORM 8-K | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-13 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-01-13 | Insider transaction (Form 4) | view · |
| 8-K | 2025-01-08 | FORM 8-K | view · |
| 4 | 2024-12-10 | Insider transaction (Form 4) | view · |
| 8-K | 2024-12-10 | FORM 8-K | view · |
| 10-Q | 2024-11-12 | FORM 10-Q | view · |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Options picks · CMPX
ITM + OTM ideas from the latest scanLoading…
Congress trades · CMPX
STOCK Act disclosuresLoading…
SEC filings & insiders · CMPX
EDGAR · liveLoading…
Holders · CMPX
Institutions & insider activityLoading…